Major Key Takeaways

• Erosion of Federal Infrastructure: Recent federal workforce reductions and funding cuts at the CDC, NIH, and FDA have significantly undermined the nation's reproductive health infrastructure. The elimination of the CDC’s Assisted Reproductive Technology (ART) Surveillance Team has effectively halted the federal reporting of IVF success rates required by law, reducing transparency for patients.
• Military Readiness and Family Building: Infertility affects service members at higher rates than the general population, yet TRICARE currently only covers IVF for those with service-connected injuries. Expanding comprehensive coverage to all active-duty members is estimated to cost just $1.6 billion over ten years, a modest investment that would significantly improve military retention and diversity.
• Highly Regulated Landscape: Contrary to public perception, Assisted Reproduction and IVF Policy in the United States is governed by a robust network of state licensing, federal oversight (via the FDA and CMS), and professional self-regulation through organisations like ASRM and SART.
• The Critical Role of Insurance Mandates: States with insurance mandates for IVF show better clinical outcomes, such as lower rates of high-order multiple births, because patients feel less financial pressure to transfer multiple embryos in a single cycle.
• Evidence-Based Care vs. Alternatives: While "Restorative Reproductive Medicine" (RRM) is frequently promoted as a natural alternative to IVF, current scientific reviews find no high-quality evidence that RRM is as effective as established assisted reproductive technologies.
• Equity and Reproductive Justice: Employer-subsidised fertility benefits are becoming more common among large corporations, but they often prioritise high-income, white-collar workers. This can lead to "reproductive job lock," where marginalised workers feel compelled to remain in distressing conditions simply to access the care needed to build a family.

Reproductive medicine is a fundamental branch of healthcare that encompasses the entire human life cycle, from puberty and contraception to infertility and menopause. As the demand for advanced fertility treatments grows, highlighted by the fact that over 2% of all U.S. births now result from IVF—the policy environment surrounding these services has become increasingly complex and politicised.

A primary concern for the field is the recent "defunding" of federal scientific governance. In early 2025, sweeping workforce reductions at the Department of Health and Human Services (HHS) led to an 18% staff loss, including the total disbandment of the CDC’s ART Surveillance Team. This team was responsible for executing the Fertility Clinic Success Rate and Certification Act (FCSRCA), which mandated the reporting of clinic-level data so that patients could make informed choices. Without this federal oversight, a significant gap in transparency has emerged, potentially weakening patient protections and quality benchmarking across the nation's clinics. Similarly, funding freezes and terminations for thousands of NIH grants have disrupted critical research into uterine fibroids, maternal health, and reproductive biology.

Parallel to these federal challenges is the urgent need to address the "double bind" faced by military families. Service members must navigate frequent deployments and training cycles that complicate natural conception, yet they often face prohibitive out-of-pocket costs for fertility care averaging $15,000 to $30,000 per patient. Expanding Assisted Reproduction and IVF Policy to provide permanent, comprehensive benefits for all active-duty service members is not just a moral imperative; it is a national security priority that bolsters the military's ability to retain top talent and female leadership.

Furthermore, the integrity of clinical practice is under pressure from the promotion of non-evidence-based alternatives. Political movements have increasingly championed "Restorative Reproductive Medicine" (RRM) as a substitute for IVF. However, systematic reviews of RRM interventions, including treatments for vitamin deficiencies and immune factors, find limited evidence of their effectiveness in treating most forms of infertility. ASRM remains committed to ensuring that clinical decisions remain grounded in rigorous science rather than political or ideological narratives.

The economic landscape is also shifting as more private employers begin to subsidize reproductive care. While companies like Starbucks and Amazon have expanded access for their employees, these benefits are not universal. This stratification of care means that a woman’s ability to control her reproduction is often tied directly to her socioeconomic status or her specific employer. True reproductive justice requires a shift toward a more equitable system, including national insurance mandates that ensure all Americans regardless of race, income, or zip code have the resources to build their families safely.

In conclusion, the future of Assisted Reproduction and IVF Policy must focus on stabilizing federal research funding, restoring regulatory capacity at the FDA and CDC, and eliminating the discriminatory barriers that prevent service members and marginalised populations from accessing care. Safeguarding this infrastructure is essential for maintaining the United States’ position as a global leader in medical innovation and ensuring that the dream of parenthood remains attainable for all.